JP2014515036A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014515036A5 JP2014515036A5 JP2014510798A JP2014510798A JP2014515036A5 JP 2014515036 A5 JP2014515036 A5 JP 2014515036A5 JP 2014510798 A JP2014510798 A JP 2014510798A JP 2014510798 A JP2014510798 A JP 2014510798A JP 2014515036 A5 JP2014515036 A5 JP 2014515036A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- maytansinoid immunoconjugate
- maytansinoid
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11290232A EP2524929A1 (en) | 2011-05-17 | 2011-05-17 | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| EP11290232.5 | 2011-05-17 | ||
| PCT/EP2012/059141 WO2012156455A1 (en) | 2011-05-17 | 2012-05-16 | Use of anti-cd19 maytansinoid immunoconjugate antibody for the treatment of b-cell malignancies symptoms |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016226407A Division JP6181273B2 (ja) | 2011-05-17 | 2016-11-22 | Ｂ細胞悪性腫瘍の症状の治療のための抗ｃｄ１９メイタンシンノイドイムノコンジュゲート抗体の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014515036A JP2014515036A (ja) | 2014-06-26 |
| JP2014515036A5 true JP2014515036A5 (enExample) | 2014-08-07 |
| JP6050328B2 JP6050328B2 (ja) | 2016-12-21 |
Family
ID=46085972
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014510798A Expired - Fee Related JP6050328B2 (ja) | 2011-05-17 | 2012-05-16 | Ｂ細胞悪性腫瘍の症状の治療のための抗ｃｄ１９メイタンシンノイドイムノコンジュゲート抗体の使用 |
| JP2016226407A Expired - Fee Related JP6181273B2 (ja) | 2011-05-17 | 2016-11-22 | Ｂ細胞悪性腫瘍の症状の治療のための抗ｃｄ１９メイタンシンノイドイムノコンジュゲート抗体の使用 |
| JP2017138852A Pending JP2018021020A (ja) | 2011-05-17 | 2017-07-18 | Ｂ細胞悪性腫瘍の症状の治療のための抗ｃｄ１９メイタンシンノイドイムノコンジュゲート抗体の使用 |
| JP2019087962A Pending JP2019142961A (ja) | 2011-05-17 | 2019-05-08 | Ｂ細胞悪性腫瘍の症状の治療のための抗ｃｄ１９メイタンシンノイドイムノコンジュゲート抗体の使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016226407A Expired - Fee Related JP6181273B2 (ja) | 2011-05-17 | 2016-11-22 | Ｂ細胞悪性腫瘍の症状の治療のための抗ｃｄ１９メイタンシンノイドイムノコンジュゲート抗体の使用 |
| JP2017138852A Pending JP2018021020A (ja) | 2011-05-17 | 2017-07-18 | Ｂ細胞悪性腫瘍の症状の治療のための抗ｃｄ１９メイタンシンノイドイムノコンジュゲート抗体の使用 |
| JP2019087962A Pending JP2019142961A (ja) | 2011-05-17 | 2019-05-08 | Ｂ細胞悪性腫瘍の症状の治療のための抗ｃｄ１９メイタンシンノイドイムノコンジュゲート抗体の使用 |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US9555126B2 (enExample) |
| EP (2) | EP2524929A1 (enExample) |
| JP (4) | JP6050328B2 (enExample) |
| KR (1) | KR20140043388A (enExample) |
| CN (2) | CN107007840A (enExample) |
| AR (1) | AR086412A1 (enExample) |
| AU (3) | AU2012258254B2 (enExample) |
| BR (1) | BR112013029330A8 (enExample) |
| CA (1) | CA2835738A1 (enExample) |
| CL (1) | CL2013003272A1 (enExample) |
| CO (1) | CO6821893A2 (enExample) |
| CR (1) | CR20130593A (enExample) |
| DO (1) | DOP2013000260A (enExample) |
| EA (1) | EA028574B1 (enExample) |
| EC (1) | ECSP13013084A (enExample) |
| GT (1) | GT201300276A (enExample) |
| IL (3) | IL229380B (enExample) |
| MA (1) | MA35180B1 (enExample) |
| MX (1) | MX347019B (enExample) |
| MY (1) | MY163736A (enExample) |
| NI (1) | NI201300119A (enExample) |
| PE (1) | PE20141018A1 (enExample) |
| PH (2) | PH12013502305A1 (enExample) |
| SG (2) | SG194894A1 (enExample) |
| TN (1) | TN2013000468A1 (enExample) |
| TW (3) | TW201834687A (enExample) |
| UA (1) | UA114401C2 (enExample) |
| UY (1) | UY34077A (enExample) |
| WO (1) | WO2012156455A1 (enExample) |
| ZA (1) | ZA201309400B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2524929A1 (en) * | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| EP2777714A1 (en) * | 2013-03-15 | 2014-09-17 | NBE-Therapeutics LLC | Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme |
| CN113150145B (zh) | 2013-08-30 | 2025-02-14 | 伊缪诺金公司 | 用于检测叶酸受体1的抗体和测定 |
| CN105837689B (zh) * | 2015-01-13 | 2020-06-19 | 博生吉安科细胞技术有限公司 | 抗cd19单克隆抗体及其制备方法 |
| WO2016180941A1 (en) * | 2015-05-13 | 2016-11-17 | Sanofi | Liquid compositions for anti-cd19 antibody-drug conjugates |
| LT3302550T (lt) | 2015-05-26 | 2019-11-11 | Morphosys Ag | Anti-cd19 antikūno ir brutono tirozino kinazės inhibitoriaus derinys ir jo naudojimas |
| RU2767063C2 (ru) | 2015-08-21 | 2022-03-16 | МорфоСис АГ | Комбинации и их использование |
| CN116440279B (zh) | 2015-09-17 | 2026-02-24 | 伊缪诺金公司 | 包含抗folr1免疫缀合物的治疗组合 |
| US20170189548A1 (en) | 2015-11-25 | 2017-07-06 | Immunogen, Inc. | Pharmaceutical formulations and methods of use thereof |
| FI3916392T3 (fi) | 2016-05-30 | 2024-06-03 | Incyte Corp | Menetelmiä cd19-vasta-ainehoidon terapeuttisen hyödyn ennakoimiseksi potilailla |
| WO2018002031A1 (en) | 2016-06-27 | 2018-01-04 | Morphosys Ag | Anti-cd19 antibody formulations |
| US12358983B2 (en) | 2016-10-28 | 2025-07-15 | Incyte Corporation | Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof |
| WO2018183494A1 (en) * | 2017-03-31 | 2018-10-04 | Immunogen, Inc. | Cd19-targeting antibody-drug conjugates |
| EP3612839A1 (en) * | 2017-04-20 | 2020-02-26 | ADC Therapeutics SA | Combination therapy |
| CA3064804A1 (en) | 2017-06-14 | 2018-12-20 | Adc Therapeutics Sa | Dosage regimes for the administration of an anti-cd19 adc |
| EP3684820A4 (en) * | 2017-09-21 | 2021-05-26 | Wuxi Biologics (Cayman) Inc. | NEW ANTI-CD19 ANTIBODIES |
| KR102820804B1 (ko) | 2017-09-22 | 2025-06-16 | 우시 바이올로직스 아일랜드 리미티드 | 신규한 이중특이적 cd3/cd19 폴리펩티드 복합체 |
| US11274121B2 (en) | 2018-01-12 | 2022-03-15 | Immunogen, Inc. | Methods for antibody drug conjugation, purification, and formulation |
| SG11202110922QA (en) | 2019-04-26 | 2021-10-28 | Immunogen Inc | Camptothecin derivatives |
| AU2020267823A1 (en) | 2019-05-03 | 2021-11-11 | Incyte Corporation | Anti-CD19 therapy in patients having a limited number of NK cells |
| CN115151565A (zh) | 2019-10-31 | 2022-10-04 | 莫佛塞斯公司 | 包含抗CD19抗体和γδT细胞的抗肿瘤组合疗法 |
| TW202525340A (zh) | 2019-10-31 | 2025-07-01 | 美商英塞特公司 | 用於治療白血病或淋巴瘤之抗cd19療法與來那度胺(lenalidomide)的組合 |
| JP2022552748A (ja) * | 2019-10-31 | 2022-12-19 | フォーティ セブン， インコーポレイテッド | 抗ｃｄ４７及び抗ｃｄ２０による血液癌の治療 |
| CN110845617B (zh) * | 2019-12-05 | 2021-07-09 | 常州费洛斯药业科技有限公司 | 针对cd19的全人源抗体或抗体片段、嵌合抗原受体及应用 |
| WO2021259902A1 (en) | 2020-06-22 | 2021-12-30 | Morphosys Ag | Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirpα-cd47 innate immune checkpoint |
| WO2022076573A1 (en) | 2020-10-06 | 2022-04-14 | Xencor, Inc. | Biomarkers, methods, and compositions for treating autoimmune disease including systemic lupus erythematous (sle) |
| WO2022117799A2 (en) | 2020-12-04 | 2022-06-09 | Morphosys Ag | Anti-cd19 combination therapy |
| WO2023073645A1 (en) | 2021-10-29 | 2023-05-04 | Takeda Pharmaceutical Company Limited | Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor |
| KR20250052388A (ko) | 2022-08-17 | 2025-04-18 | 인사이트 코포레이션 | 항-cd19 항체 및 ezh2 조절제를 포함하는 요법 |
| WO2025087382A1 (zh) * | 2023-10-26 | 2025-05-01 | 上海先博生物科技有限公司 | 靶向cd19的嵌合抗原受体的治疗用途 |
| WO2025157132A1 (en) | 2024-01-23 | 2025-07-31 | Wuxi Biologics (Shanghai) Co., Ltd. | Multispecific antibodies targeting cd3, cd19 and cd20 and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002220265A1 (en) * | 2000-11-03 | 2002-05-15 | University Of Vermont And State Agricultural College | Compositions for inhibiting grb7 |
| MXPA05011811A (es) * | 2003-05-20 | 2006-02-17 | Immunogen Inc | Agentes citotoxicos mejorados que comprenden nuevos maitansinoides. |
| RU2495882C2 (ru) * | 2006-09-08 | 2013-10-20 | Медиммун, Ллк. | Гуманизированные антитела к cd19 и их применение для лечения онкологического, связанного с трансплантацией и аутоиммунного заболевания |
| RU2683325C2 (ru) * | 2009-02-05 | 2019-03-28 | Иммьюноджен, Инк. | Новые производные бензодиазепина |
| CA2761120A1 (en) * | 2009-05-06 | 2010-11-11 | Biotest Ag | Uses of immunoconjugates targeting cd138 |
| EP2490715A4 (en) * | 2009-10-21 | 2013-06-26 | Immunogen Inc | NEW DOSAGE ADMINISTRATION REGIMEN AND METHOD OF TREATMENT |
| EP2524929A1 (en) * | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| EP2550975A1 (en) * | 2011-07-29 | 2013-01-30 | Sanofi | Combination therapy for the treatment of CD19+ B-cell malignancies symptoms comprising an anti-CD19 maytansinoid immunoconjugate and rituximab |
-
2011
- 2011-05-17 EP EP11290232A patent/EP2524929A1/en not_active Ceased
-
2012
- 2012-05-16 MY MYPI2013004057A patent/MY163736A/en unknown
- 2012-05-16 BR BR112013029330A patent/BR112013029330A8/pt not_active IP Right Cessation
- 2012-05-16 EA EA201391714A patent/EA028574B1/ru not_active IP Right Cessation
- 2012-05-16 SG SG2013083407A patent/SG194894A1/en unknown
- 2012-05-16 CN CN201611022631.9A patent/CN107007840A/zh active Pending
- 2012-05-16 JP JP2014510798A patent/JP6050328B2/ja not_active Expired - Fee Related
- 2012-05-16 AU AU2012258254A patent/AU2012258254B2/en not_active Ceased
- 2012-05-16 PH PH1/2013/502305A patent/PH12013502305A1/en unknown
- 2012-05-16 US US14/117,806 patent/US9555126B2/en not_active Expired - Fee Related
- 2012-05-16 WO PCT/EP2012/059141 patent/WO2012156455A1/en not_active Ceased
- 2012-05-16 PE PE2013002503A patent/PE20141018A1/es not_active Application Discontinuation
- 2012-05-16 KR KR1020137033076A patent/KR20140043388A/ko not_active Abandoned
- 2012-05-16 CA CA2835738A patent/CA2835738A1/en not_active Abandoned
- 2012-05-16 SG SG10201609729VA patent/SG10201609729VA/en unknown
- 2012-05-16 CN CN201280023918.7A patent/CN103547596A/zh active Pending
- 2012-05-16 EP EP12721529.1A patent/EP2710034A1/en not_active Withdrawn
- 2012-05-16 MX MX2013013455A patent/MX347019B/es active IP Right Grant
- 2012-05-16 AR ARP120101724A patent/AR086412A1/es unknown
- 2012-05-16 UA UAA201314732A patent/UA114401C2/uk unknown
- 2012-05-17 TW TW107102069A patent/TW201834687A/zh unknown
- 2012-05-17 UY UY0001034077A patent/UY34077A/es not_active Application Discontinuation
- 2012-05-17 TW TW105134320A patent/TW201726167A/zh unknown
- 2012-05-17 TW TW101117628A patent/TWI601537B/zh not_active IP Right Cessation
-
2013
- 2013-11-11 IL IL229380A patent/IL229380B/en active IP Right Grant
- 2013-11-12 NI NI201300119A patent/NI201300119A/es unknown
- 2013-11-12 TN TNP2013000468A patent/TN2013000468A1/fr unknown
- 2013-11-12 DO DO2013000260A patent/DOP2013000260A/es unknown
- 2013-11-12 GT GT201300276A patent/GT201300276A/es unknown
- 2013-11-13 CR CR20130593A patent/CR20130593A/es unknown
- 2013-11-14 CL CL2013003272A patent/CL2013003272A1/es unknown
- 2013-12-12 MA MA36558A patent/MA35180B1/fr unknown
- 2013-12-12 ZA ZA2013/09400A patent/ZA201309400B/en unknown
- 2013-12-16 CO CO13293559A patent/CO6821893A2/es unknown
- 2013-12-16 EC ECSP13013084 patent/ECSP13013084A/es unknown
-
2016
- 2016-07-21 AU AU2016206317A patent/AU2016206317A1/en not_active Abandoned
- 2016-11-22 JP JP2016226407A patent/JP6181273B2/ja not_active Expired - Fee Related
- 2016-12-16 US US15/381,266 patent/US20170196988A1/en not_active Abandoned
-
2017
- 2017-07-18 JP JP2017138852A patent/JP2018021020A/ja active Pending
- 2017-07-28 PH PH12017501368A patent/PH12017501368A1/en unknown
-
2018
- 2018-02-12 IL IL257475A patent/IL257475A/en unknown
- 2018-03-01 AU AU2018201504A patent/AU2018201504A1/en not_active Abandoned
- 2018-12-16 IL IL263728A patent/IL263728A/en unknown
-
2019
- 2019-05-08 JP JP2019087962A patent/JP2019142961A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014515036A5 (enExample) | ||
| JP6181273B2 (ja) | Ｂ細胞悪性腫瘍の症状の治療のための抗ｃｄ１９メイタンシンノイドイムノコンジュゲート抗体の使用 | |
| TWI596116B (zh) | 包含專一性辨識ｃｄ３８之抗體及硼替佐米（ｂｏｒｔｅｚｏｍｉｂ）之抗腫瘤組合 | |
| Cang et al. | Novel CD20 monoclonal antibodies for lymphoma therapy | |
| TWI549690B (zh) | 包含抗－ｃｄ１９類美登素（ｍａｙｔａｎｓｉｎｏｉｄ）免疫結合物及利妥昔單抗（ｒｉｔｕｘｉｍａｂ）之用於治療ｃｄ１９＋ｂ－細胞惡性症狀之組合療法 | |
| JP2016531915A5 (enExample) | ||
| JP2018500014A5 (enExample) | ||
| JP2016538318A5 (enExample) | ||
| KR20140019298A (ko) | Dlbcl의 치료 수단 및 방법 | |
| JP2014533279A5 (enExample) | ||
| JP2020536112A (ja) | Ｔ細胞免疫療法のための組合せ及びその使用 | |
| WO2017066583A1 (en) | A nanomaterial complex comprising graphene oxide associated with a therapeutic agent and methods of use | |
| JP2015500822A5 (enExample) | ||
| JP2021501776A5 (enExample) | ||
| JP2020510039A5 (enExample) | ||
| EP2849784A1 (en) | Combination of cd37 antibodies with ice (ifosfamide, carboplatin, etoposide) | |
| JP2015517512A (ja) | Ｃｄ３７抗体の更なる薬剤との併用 | |
| JP2016525560A5 (enExample) | ||
| JP2024028865A (ja) | 抗ｃｄ１９抗体とベネトクラクスとの組み合わせ治療のための治療パラダイム | |
| US20230014026A1 (en) | Anti-Tumor Combination Therapy comprising Anti-CD19 Antibody and Polypeptides Blocking the SIRPalpha-CD47 Innate Immune Checkpoint | |
| JP2015516980A (ja) | Ｃｄ３７抗体とベンダムスチンとの併用 | |
| CN120437318A (zh) | 抗体药物偶联物和免疫检查点抑制剂的联合应用 | |
| Doubek et al. | Treatment of chronic lymphocytic leukemia with monoclonal antibodies, where are we heading? | |
| Stathis et al. | New agents for the treatment of lymphoma | |
| US20160106837A1 (en) | Combination of cd37 antibodies with chlorambucil |